This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Chen LL , Nguyen TB , Jones E , Chen ZQ , Luo W , Wang L , Price RA , Pollack A , Ma CMC
Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: Creation of digitally reconstructed radiographs
International Journal of Radiation Oncology Biology Physics. 2007 Jul;68(3) :903-911
AbstractPurpose: To develop a technique to create magnetic resonance (MR)-based digitally reconstructed radiographs (DRR) for initial patient setup for routine clinical applications of MR-based treatment planning for prostate intensity-modulated radiotherapy. Methods and Materials: Twenty prostate cancer patients' computed tomography (CT) and MR images were used for the study. Computed tomography and MR images were fused. The pelvic bony structures, including femoral heads, pubic rami, ischium, and ischial tuberosity, that are relevant for routine clinical patient setup were manually contoured on axial MR images. The contoured bony structures were then assigned a bulk density of 2.0 g/cm(3). The MR-based DRRs were generated. The accuracy of the MR-based DDRs was quantitatively evaluated by comparing MR-based DRRs with CT-based DRRs for these patients. For each patient, eight measuring points on both coronal and sagittal DRRs were-used for quantitative evaluation. Results: The maximum difference in the mean values of these measurement points was 1.3 +/- 1.6 mm, and the maximum difference in absolute positions was within 3 rum for the 20 patients investigated. Conclusions: Magnetic resonance-based DRRs are comparable to CT-based DRRs for prostate intensity-modulated radiotherapy and can be used for patient treatment setup when MR-based treatment planning is applied clinically. (c) 2007 Elsevier Inc.
NotesISI Document Delivery No.: 179JB Times Cited: 0 Cited Reference Count: 19 Cited References: AM AM, 2003, INT J RADIAT ONCOL, V56, P199 BUYYOUNOUSKI MK, 2004, INT J RADIAT ONCOL, V59, P1383 CHEN LL, 2004, INT J RADIAT ONCOL, V60, P636 HANKS GE, 1998, INT J RADIAT ONCOL, V41, P501 HANKS GE, 1999, ACTA ONCOL S13, V38, P69 HUNT MA, 2001, INT J RADIAT ONCOL, V49, P623 KHOO VS, 2000, INT J RADIAT ONCOL, V46, P1309 KREMPIEN RC, 2002, INT J RADIAT ONCOL, V53, P1350 POLLACK A, 1999, SEMIN ONCOL, V26, P150 POLLACK A, 2000, J CLIN ONCOL, V18, P3304 POLLACK A, 2002, INT J RADIAT ONCOL, V53, P1097 POTTER R, 1992, RADIOTHER ONCOL, V23, P127 RASCH C, 1999, INT J RADIAT ONCOL, V43, P57 SANNAZZARI GL, 2002, BRIT J RADIOL, V75, P603 STEENBAKKERS RJHM, 2003, INT J RADIAT ONCOL, V57, P1269 TANNER SF, 2000, PHYS MED BIOL, V45, P2117 WACHTER S, 2002, STRAHLENTHER ONKOL, V178, P263 YEOH EEK, 2003, INT J RADIAT ONCOL, V55, P943 ZELEFSKY MJ, 1998, INT J RADIAT ONCOL, V41, P491